Navigation Links
Transgenomic Reports Second Quarter Financial Results
Date:8/11/2011

arter in 2010. Within this business our pharmacogenomics research services grew 223% to $1.0 million for the second quarter of 2011. We expect to continue seeing strong performance in this segment," commented Craig Tuttle, President and Chief Executive Officer for the company. "Testing volume and revenues increased in both our Neurology lab business and in our FAMILION product group with sales of $1.2 million for Neurology and $2.6 million for FAMILION. We expect these lab areas to continue growing due to new test offerings and further sales penetration into their respective markets. The FAMILION tests are an important means of identifying cardiac channelopathies, potentially life threatening defects in the heart.  Both doctors and patients recognize the benefit that these tests provide in at risk populations, and we expect to continue to expand this franchise."

"As we experienced in the first quarter, and again this quarter, our significant stock price increase has resulted in non-cash charges due to the revaluation of our preferred stock conversion feature and warrant liability," Tuttle continued. "In the first quarter, this resulted in an expense of $2 million and, with further strengthening of our share price in second quarter; the expense reached an additional $4.2 million bringing the total expense for the first six months of 2011 to $6.3 million. While this non-cash expense appears significant, I want to emphasize that it does not affect our cash flow.  I trust that shareholders are encouraged by the growth in our market capitalization since we secured this financing and acquired the FAMILION Business."

Modified EBITDA, which we are emphasizing as an appropriate and sound measure of our real business results, improved to $(369,000) in the second quarter of 2011 from $(939,000) in the second quarter of 2010.

Transgenomic anticipates growth in both our diagnostics and our laboratory services businesses as we commercialize new assa
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic to Hold First Quarter Financial Results Conference Call on May 12, 2011
2. Transgenomic, Inc. Enhances FAMILION® Genetic Test Offerings
3. Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting
4. Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1%
5. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
6. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
7. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
8. Transgenomic Reports Third Quarter Financial Results
9. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
10. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
11. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a ... Drug Administration (FDA) for the use of Medtronic,s ... (including a newly developed catheter) for use with ... intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... 23, 2014 The report ... as its definition, classification, application and industry ... manufacturing process, and product cost structure. Production ... The analysis also covers upstream raw materials, ... development trend and proposals. In the end, ...
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... YM Enrolls First Patients in Multinational Randomized, Double-Blind Brain, ... Sept. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... development company that identifies and advances a diverse portfolio ... today reported that nimotuzumab has been approved for marketing ...
... ... Henry "Pete" Linsert, Jr. has joined its Board of Directors. , ... Alachua, FL (PRWEB) September 16, 2009 ... Board of Directors., , ,Mr. Linsert is President and CEO of Columbia Biosciences Corporation ...
... , , , RICHMOND, Calif., ... announced today that Edward Lanphier, Sangamo,s president and CEO, will provide ... and an overview of the company,s business strategy at 1:30 pm ... Sciences Conference which will be held in New York City. , ...
Cached Biology Technology:YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 2YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 4NovaMin Technology Inc. Welcomes New Board Member 2Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference 2
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... A plant,s immune system protects the plant from ... can stunt plant growth and reduce seed production. Now, ... negatively regulate the responses of the immune system in ... immune system of plants would allow breeders to create ...
... Premature ejaculation can be embarrassing, but a new study ... Researchers from Turku, Finland, interviewed more than three thousand ... older or younger brothers - about the first time ... that they had suffered from erectile dysfunction and premature ...
... very latest information on the 2009 swine influenza (H1N1) ... hosted by the New York Academy of Sciences on ... virus, epidemiology, treatment, vaccine development and the public health ... required to attend the conference, held from 12:30 p.m. ...
Cached Biology News:Understanding plants' overactive immune system will help MU researchers build better crops 2
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
cystatin A (N-18)...
Human Cystatin A MAb (Clone 224705)...
Biology Products: